Antitumor activity of 4-phenyl-1-arylsulfonylimidazolidinone, DW2143

Cancer Letters

Volumn 140, Issue 1-2, 1999, Pages 177-187

  Moon, Eun Yi ^a   Seong, Seung Kyoo ^a   Jung, Sang Hun ^c   Lee, Moonsun ^a   Lee, Dug Keun ^a   Rhee, Dong Kwon ^b   Pyo, Suhkneung ^b   Yoon, Sung June ^a  

^a DongWha Pharm Ind Co   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Chungnam National University   (South Korea)

Author keywords

Antitumor activity; DW2143; Tumor cell growth inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; DW 2143; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL DIVISION; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; SPECIFIC PATHOGEN-FREE ORGANISMS; SULFONES; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0032972145     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00070-1     Document Type: Article

References (27)

1. Howbert J.J. Sulofenur. Drug Future. 16:1991;517-520.
2. Mohamadi F., Spees M.M., Grindey G.B. Sulfonylureas: a new class of cancer therapeutic agents. J. Med. Chem. 35:1992;3012-3016.
3. Houghton P.J., Bailey F.C., Germain G.S., Grindey G.B., Witt B.C., Houghton J.A. N-(5-Indanylsulfonyl)-N′-(4-chlorophenyl)urea, a novel agent equally cytotoxic to nonproliferating human colon adenocarcinoma cells. Cancer Res. 50:1990;318-322.
4. Houghton P.J., Bailey F.C., Houghton J.A., Murti K.G., Howbert J.J., Grindey G.B. Evidence for mitochondrial localization of N-(4-methylphenylsulfonyl)-N′-(4-chlorophenyl)urea in human colon adenocarcinoma cells. Cancer Res. 50:1990;664-668.
5. Houghton P.J., Houghton J.A., Meyers L., Cheshire P., Howbert J.J., Grindey G.B. Evaluation of N-(5-indanylsulfonyl)-N′-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother. Pharmacol. 25:1989;84-88.
6. Howbert J.J., Grossman C.S., Crowell T.A., Rieder B.J., Harper R.W., Kramer K.E., Tao E.V., Aikins J., Poore G.A., Rinzel S.M., Grindey G.B., Shaw W.N., Todd G.C. Novel agents effective against solid tumors: the diarylsulfonylureas: synthesis, activities and analysis of quantitative structure-activity relationships. J. Med. Chem. 33:1990;2393-2407.
7. Ehlhardt W.J., Woodland J.M., Toth J.E., Ray J.E., Martin D.L. Disposition and metabolism of the sulfonylurea oncolytic agent LY295501 in mouse, rat and monkey. Drug Metab. Dispos. 25:1997;701-708.
8. Houghton P.J., Houghton J.A. Antitumor diarylsulfonylureas: novel agents with unfulfilled promise. Invest. New Drugs. 14:1996;271-280.
9. Sosinski J., Thakar J.H., Germain G.S., Dias P., Harwood F.C., Kuttesch J.F., Houghton P.J. Cross-resistance of antitumor diarylsulfonylureas, and collateral sensitivity to mitochondrial toxins in a human cell line selected for resistance to the antitumor agent N-(5-indanylsulfonyl)-N′-(4-chlorophenyl)urea. Mol. Pharmacol. 45:1994;962-970.
10. Boder G.B., Beasley F.W., Grindey G.B. Mechanism of action studies with LY186641. Proc. Am. Assoc. Cancer Res. 30:1989;2203. (abstr.).
11. Houghton P.J., Bailey F.C., Germain G.S., Grindey G.B., Howbert J.J., Houghton J.A. Studies on the cellular pharmacology of N-(4-methylphenylsulfonyl)-N′-(4-chlorophenyl)urea. Biochem. Pharmacol. 39:1990;1187-1192.
12. Taylor C.W., Albert D.S., Peng Y.M., McCloskey T.M., Matzner M., Roe D.J., Plezia P.M., Grindey G.B., Hamilton M., Seitz D. Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer. J. Natl. Cancer Inst. 84:1992;1798-1802.
13. Talbot D.C., Smith I.E., Nicolson M.C., Powles T.J., Burton D., Walling J. Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer. Cancer Chemother. Pharmacol. 31:1993;419-422.
14. Hainworth J.D., Hande K.R., Satterlee W.G., Kuttesch J., Johnson D.H., Grindey G.B., Jackson L.E., Greco F.A. Phase I clinical study of N-[(4-chlorophenyl)-amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641). Cancer Res. 49:1989;5217-5220.
15. Jung S.H., Song J.S., Lee H.S., Choi S.H., Lee C.O. Synthesis and evaluation of cytotoxicity of novel arylsulfonylimidazolidinones containing sulfonylurea pharmacophore. Arch. Pharm. Res. 19:1996;570-580.
16. Jung S.H., Song J.S., Lee H.S., Choi S.H., Lee C.O. Synthesis and evaluation of cytotoxicity of novel arylsulfonylimidazolidinones. Bioorg. Med. Chem. Lett. 6:1996;2553-2558.
17. Jung S.H., Lee H.S., Song J.S., Kim H.M., Han S.B., Lee C.W., Lee M., Choi D.R., Lee J.A., Chung Y.H., Yoon S.J., Moon E.Y., Hwang H.S., Seong S.K., Lee D.K. Synthesis and antitumor activity of 4-phenyl-1-arylsulfonyl imidazolidinones. Bioorg. Med. Chem. Lett. 8:1998;1547-1550.
18. Chen H.X., Bamberger U., Heckel A., Guo X., Cheng Y.C. BIBW22, a dipyridamole analog, acts as a bifunctional modulator in tumor cells by influencing both p-glycoprotein. Cancer Res. 53:1993;1974-1977.
19. Mosman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
20. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.F., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:1987;936-942.
21. Graeme J.F., Bruce C.B., William R.W. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal. Biochem. 139:1984;272-277.
22. Geran R.I., Greenberg N.H., McDonald M.M., Schumacher A.M., Abbott B.J. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep. 3:1972;1.
23. Grindey G.B. Identification of diarylsulfonylurea as novel anticancer drugs. Proc. Am. Assoc. Cancer Res. 29:1988;535.
24. Munshi N.C., Seitz D.E., Fossella F., Lippman S.M., Einhorn L.H. Phase II study of sulofenur (LY 41), a novel anti-neoplastic agent in advanced non-small lung cancer. Proc. Am. Assoc. Cancer Res. 32:1991;189.
25. Shultz R.M., Merriman R.L., Toth J.E., Zimmermann J.E., Hertel L.W., Andis S.L., Dudley D.E., Rutherford P.G., Tanzer L.R., Grindey G.B. Evaluation of new anticancer agents against the MIA Paca-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol. Res. 5:1993;223.
26. Grindey G.B. Current status of cancer drug development: Failure or limited success? Cancer Cells. 2:1990;163-171.
27. Davis S.N., Granner D.K. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. The Pharmacological Basis of Therapeutics. 1996;McGraw-Hill, New York.